Supplementary Figures S1-S8 from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Figure S1: Treatment response to cisplatin spread over several days. Figure S2: Cisplatin adducts in tumor remants; GFP-marker in the BRCA1-deficient mouse model. Figure S3: EdU incorporation assay. Figure S4: Genomic profile and clonogenic assays of BRCA1-deficient cell lines. Figure S5: Determination of IC50 in KB1P-B11 and -G3; Cell cycle dependent cell death of KB1P-B11-FUCCI. Figure S6: Drug response to nimustine, melphalan, bendamustine or temozolomide. Figure S7: High dose treatment of mice with carboplatin or thiotepa. Figure S8: Combination or single treatment with cyclophosphamide, carboplatin or thiotepa.</p
